Abstract: Objective: To evaluate the clinical efficacy and safety of apatinib combined with S-1 in patients with local advanced squamous cell carcinoma of the head-and-neck. Methods: Apatinib is a tyrosine kinase inhibitor of a highly selective vascular endothelial growth factor receptor-2, the targeting therapy drug. S-1 is an oral fluoropyrimidine (FU) anticancer agent. Two patients with local advanced (T4N0M0) squamous cell carcinoma of the tongue were accepted the combining therapy（Apatinib 500 mg a time and once a day， and S-1 20 mg each time and 3 times a day） were given orally. Clinical efficacy and safety of the combining therapy were evaluated. Results: For case 1 patient, seven weeks after the treatment the tumor was completely faded both clinically and in MR scanning. No cancer cell could be found in resected tissue of primary site of the tongue during pathological examination , which showed the result of pathological complete response (pCR). For case 2 patient, 2 month after the treatment， the tumor reduced more than 50% volume both clinically and in MR scanning and continue to shrink during 5- month after the treatment. That showed the result of clinical partial response (cPR). All 2 patients under combining therapy was generally tolerable and toxicities were controllable. Conclusion: The efficacy of the combining therapy is remarkable , and with tolerable adverse reactions in two patients, that may be considered by oncology practioners.

Key words: targeting therapy； apatinib, S-1, squamous cell carcinoma of tongue, oral squamous cell carcinoma

摘要： 目的：本研究评估观察阿帕提尼（Apatinib）联合替吉奥（S-1）治疗局部晚期头颈部鳞癌患者的疗效和安全性。方法：阿帕提尼（Apatinib）是一种高选择性血管内皮细胞生长因子受体-2（VEFGR2）的酪氨酸激酶抑制剂靶向药，替吉奥（S-1）是口服氟脲嘧啶（FU）抗癌药。2例局部晚期（T4N0M0）舌鳞癌患者接受联合治疗：阿帕提尼片500 mg/次， 1次/d口服、替吉奥胶囊20 mg/次 3次/d口服。并评估联合治疗的临床疗效和安全性。结果：病例1治疗7周后临床和MR检查发现肿瘤完全消失，随后的舌原发部位手术标本病理检查未见癌细胞，显示病理完全缓解（pathological complete response，pCR）的结果；病例2治疗2个月后临床和MR检查发现肿瘤缩小超过50%，治疗后5个月肿瘤继续缩小，显示临床部分缓解（clinical partial response，cPR）的结果。2例患者对药物耐受良好，不良反应均可以控制。结论：二例患者采用该联合治疗的疗效显著，耐受性良好，值得对局部晚期口腔鳞癌患者扩大应用。

关键词: 靶向治疗, 阿帕替尼, 替吉奥, 舌鳞癌, 口腔鳞癌

CLC Number: 

• R732.2